INTRODUCTION: Role of Ca++ in Contraction, and Wide Variety of Effects of Calcium Antagonists

  • Nick Sperelakis
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 39)


The calcium antagonistic drugs are a relatively new class of drugs that have in common the effect of reducing Ca++ ion entry into excitable nerve and muscle cells through the voltage-dependent and time-dependent slow channels. Hence, these drugs are also known as Ca++ entry blockers, slow channel blockers, or organic calcium antagonistis (to contrast with the inorganic calcium antagonists, such as Mn++, Co++, Mg++, and La+++). The organic structure of the calcium antagonistic drugs varies widely, and the chemical formulae of some of the major sub-classes of these drugs are depicted in Figure 1.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fabiato, A and Fabiato, F: Calcium and cardiac excitation-contraction coupling. Ann. Rev. Physiol. 41, 473–484, 1979.CrossRefGoogle Scholar
  2. 2.
    Mras, S and Sperelakis, N: Bepridil (CERM-1978) and verapamil depression of contractions of rabbit aortic rings. Blood Vessels 18, 196–205, 1981.PubMedGoogle Scholar
  3. 3.
    Pang, D and Sperelakis, N: Differential actions of calcium antagonists on calcium binding to cardiac sarcolemma. Europ. J. Pharmacol. 81, 403–409, 1982.CrossRefGoogle Scholar
  4. 4.
    Pang, D and Sperelakis, N: Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles. Europ. J. Pharmacol. 87, 199–207, 1983.CrossRefGoogle Scholar
  5. 5.
    Ridgway, EB, Gordon, AM, and Martyn, DA: Hysteresis in the force-calcium relation in muscle. Science 219, 1075–1077, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Rouleau, J-L, Parmley, WW, Stevens, J, Wikman-Coffelt, J, Sievers, R, Mabley, RW, and Havel, RJ: Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. J. Am. Coll. Cardiol. 1, 1453–1460, 1983.PubMedCrossRefGoogle Scholar
  7. 7.
    Schramm, M, Thomas, G, Towart, R, and Franckowiak, G: Activation of calcium channels by novel 1,4-dihydropyridines. Arzneim. Forsch./Drug Res. 33, 1268–1272, 1983.Google Scholar
  8. 8.
    Sperelakis, N: Electrophysiology of vascular smooth muscle of coronary artery. Chap. 4. In: The Coronary Artery (S. Kalsner, ed.) Croom Helm, Ltd., London, pp. 118–167, 1982.Google Scholar
  9. 9.
    Vogel, S, Crampton, R, and Sperelakis, N: Blockade of myocardial slow channels by Bepridil (CERM-1978). J. Pharmacol. Exp. Ther. 210, 378–385, 1979.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Nick Sperelakis

There are no affiliations available

Personalised recommendations